NPM1 and acute myeloid leukemia: However, GEP had limited predictive value for AML cases with NPM1, CEBPA, KMT2A(-PTD), FLT3(-ITD), KIT, PTPN11, and N/K-RAS mutations, perhaps because of generally lower frequency of mutations in children than in adults.